@article{5fc0e04711b04902a101adfa07060385,
title = "Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab",
author = "Pavord, {Ian D.} and Roland Buhl and Monica Kraft and Prazma, {Charlene M.} and Price, {Robert G.} and Howarth, {Peter H.} and Yancey, {Steven W.}",
note = "Funding Information: Support statement: This post hoc analysis and the parent study (GlaxoSmithKline (GSK) identifier MEA112997; www.clinicaltrials.gov identifier NCT01366521) were funded by GSK. Editorial support (in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors{\textquoteright} comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Bianca Paris, PhD, of Fishawack Indicia Ltd, part of Fishawack Health, and funded by GSK. Funding information for this article has been deposited with the Crossref Funder Registry.",
year = "2022",
month = apr,
day = "1",
doi = "10.1183/23120541.00560-2021",
language = "English (US)",
volume = "8",
journal = "ERJ Open Research",
issn = "2312-0541",
publisher = "European Respiratory Society",
number = "2",
}